- Home
- HFFG vs IXHL Comparison
HFFG vs IXHL Comparison
Compare HFFG & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HFFG | IXHL |
|---|---|---|
| Founded | 1997 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Food Distributors | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.8M | 134.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HFFG | IXHL |
|---|---|---|
| Price | $2.14 | $0.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 112.7K | ★ 6.9M |
| Earning Date | 03-12-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,225,541,000.00 | $12,000.00 |
| Revenue This Year | $4.36 | N/A |
| Revenue Next Year | $3.35 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.10 | N/A |
| 52 Week Low | $1.70 | $0.08 |
| 52 Week High | $4.93 | $2.25 |
Technical Indicators
Market Signals| Indicator | HFFG | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 34.34 |
| Support Level | $2.11 | $0.34 |
| Resistance Level | $2.23 | $0.37 |
| Average True Range (ATR) | 0.09 | 0.02 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 17.16 | 3.59 |
Price Performance
Historical ComparisonAbout HFFG HF Foods Group Inc.
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The company's business consists of one operating segment; HF Group, which operates solely in the United States. The company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.